All In Biotech

Drug Trial Radar · NCT02178722

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers (ECHO-202/KEYNOTE-037)

Last checked: Nov 19, 2026Latest source record: Feb 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

444

Actual

Start

Jul 17, 2014

Primary completion

Nov 26, 2018

Study completion Nov 6, 2020

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Jul 1, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to assess the safety, tolerability, and efficacy when combining MK-3475 and INCB024360 in participants with certain cancers. This study was conducted in 2 phases, Phase 1 and Phase 2.

Conditions

  • Microsatellite-instability (MSI) High Colorectal Cancer (CRC)
  • Endometrial Cancer
  • Head and Neck Cancer
  • Hepatocellular Carcinoma (HCC)
  • Gastric Cancer
  • Lung Cancer
  • Lymphoma
  • Renal Cell Carcinoma (RCC)
  • Ovarian Cancer
  • Solid Tumors
  • UC (Urothelial Cancer)
  • Melanoma
  • Bladder Cancer
  • Triple Negative Breast Cancer (TNBC)

Interventions

  • MK-3475Drug

    IV infusion

  • INCB024360Drug

    Oral daily dosing

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Percentage of Participants With Treatment-Emergent Adverse Events (TEAE) and Serious Treatment-Emergent Adverse EventsTime frame: Approximately 54 months
  2. Phase 2: Objective Response Rate (ORR)Time frame: Approximately 54 months

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • UC San Diego Moores Cancer Center

    La Jolla, California

  • The Angeles Clinic and Research Institute

    Los Angeles, California

  • US Davis Cancer Center

    Sacramento, California

  • University Of Colorado Cancer Center

    Aurora, Colorado

  • University of Connecticut Health Center Carole And Ray Neag Comprehensive Cancer Center

    Farmington, Connecticut

  • Miami Cancer Institute at Baptist Health, Inc

    Miami, Florida

  • Georgia Cancer Specialists affiliated with Northside Hospital Cancer Institute

    Atlanta, Georgia

  • The University of Chicago Medicine

    Chicago, Illinois

  • St. Francis Cancer Center

    Topeka, Kansas

  • Greater Baltimore Cancer Center

    Baltimore, Maryland

  • St. Agnes Hospital Cancer Institute

    Baltimore, Maryland

  • The Center for Cancer and Blood Disorders (RCCA MD LLC- Maryland Division)

    Bethesda, Maryland

  • University of Michigan Hospital and Health Systems

    Ann Arbor, Michigan

  • Health Partners Institute

    Saint Louis Park, Minnesota

  • Hackensack University Medical Center - John Theurer Cancer Center

    Hackensack, New Jersey

  • The Christ Hospital Hematology Oncology, Lindner Research Center

    Cincinnati, Ohio

  • University of Pennsylvania Hospital

    Philadelphia, Pennsylvania

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • University of Pittsburgh Medical Center Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • Greenville Health System Cancer Institute

    Greenville, South Carolina

  • West Cancer Center

    Germantown, Tennessee

  • Sarah Cannon Research Institute at Tennessee Oncology

    Nashville, Tennessee

  • University Of Texas Southwestern Medical Center At Dallas

    Dallas, Texas

  • Virginia Cancer Specialists

    Arlington, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.